We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/7/2018 11:51 | Still in myself as well... Thread gone noticeably quiet since much of the hot money left. | fangorn2 | |
13/7/2018 08:10 | £44 is big possibility today . Takeda up well again overnight. | dwinn78 | |
12/7/2018 09:14 | Surprised shp have dropped this morning. | dwinn78 | |
10/7/2018 19:21 | That's ok, hope you get the result you want out of Shire. It's good to have an end goal in mind, I hit mine so that's it. | ruethewhirl | |
10/7/2018 17:04 | Couldn't help it, sorry. | mbmiah | |
10/7/2018 11:48 | Lowest form of wit mb. I'm ok with not getting the top, profit's locked in. Goodbye, farewell and amen! | ruethewhirl | |
10/7/2018 11:01 | Well done Rue lol | mbmiah | |
10/7/2018 07:28 | Takeda gets key U.S. regulatory approval to buy ShireJapan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc . Takeda has received unconditional clearance from the United States Federal Trade Commission for the Shire deal, the drugmaker said in a statement. The approval takes Takeda closer to completing a transaction that would propel it into the global ranks of drugmakers.We are still awaiting other regulatory clearances and approval by shareholders, the drugmaker added. | dwinn78 | |
10/7/2018 00:50 | Great place to exit here in my view after the recent rally. Why hold on for an extra 15% which may take a long time to realise plus the risks of deal falling over. I don't trust Shire management, I think they would throw shareholders under the bus if something happened to make the deal look not so good for themselves personally. We can say with absolute certainty that the share price will not EXCEED the offer value over the remaining time before closure and will only APPROACH the offer value over time. Very much starting to look like there are better options elsewhere for those prepared to find them. Just MHO of course :) | ruethewhirl | |
09/7/2018 13:32 | I got the impression from earlier alerts that it is likely to be Nov/Dec. They need everything in place (including regulatory approvals, details of the new shares, listing info etc) before the vote, hence the long time delay. I just hope that there is not a major global event which impacts the markets between now and then. | redtom1 | |
09/7/2018 12:44 | Any indication on when both votes are going to take place | dwinn78 | |
09/7/2018 08:34 | Value of the offer a few minutes ago, based on live fx rates, was 4925p with 2281p in cash and 2644p in shares. With current share price of 4294p, the share price would need to rise 14.70% to match. From the original offer value of 4901p, we have lost 167p in value due to fall in value of Takeda shares but gained 191p because of favourable fx movements on both the cash and share elements. Takeda (Yen) = 4630 £:$ = 1.32958 £:Yen = 146.925 | redtom1 | |
04/7/2018 20:28 | Toffeeman - there will be various funds which own SHP but which are not allowed to own non-UK listed shares. They won't have a choice but to sell the paper wihch they receive. I dont know what portion of the SHP registered this represents though as havent done the analysis. Smaller issue but there will be some retail investors who, contrary to yourself, don't want to own overseas equities | adamb1978 | |
04/7/2018 20:23 | I don't buy flow-back If a micron shareholder like me can buy and sell Takeda ADRs then anyone can. | toffeeman | |
04/7/2018 20:23 | I don't buy flow-back If a micron shareholder like me can buy and sell Takeda ADRs then anyone can. | toffeeman | |
04/7/2018 13:07 | takeda deal is going ahead 100% | swedeee | |
29/6/2018 17:43 | I think ill be holding longterm . I also think theres more danger than opportunity in the market just now so pick wisely . | dwinn78 | |
29/6/2018 08:46 | @Nig, Yeah watching SIA / SQZ with interest but not a massive fan of Oilies these days. Too many disappointments (costly) in past. Tend to stick to Shell,BP these days...have some Amerisur but they're going bloody nowhere. | fangorn2 | |
29/6/2018 08:20 | Hi Adam, just my opinion but I guess that some are selling as nigel says, he sees better opportunities elsewhere, whilst others, myself included, just want to reduce my exposure here. SHP was 20% of my pot, not nearer 10% which is a more comfortable weighting for me. I still believe that the deal will go through but if the market does take a proper nose dive (20-30% down) between now and next Spring then a lot of deals may be pulled, particularly the ones that are reliant on large amounts of debt. I've moved the funds into other shares although I know that the sensible thing to do would be to keep it as cash. | pete160 | |
29/6/2018 08:17 | Adam, you think it's a 20% gain available with no risk? People are selling because of the risk. You clearly haven't been in a share that's been under offer. The discount reflects the risk. If there was no risk, there would be no discount. For recent examples of why locking in your gains is a good idea, check out the recent Aveva / Schneider tie up. TLDR: Two approaches that fell through, followed by a third that stuck. Do you know what happens to your brain when you think you own a share that is being acquired, only to have that approach fall through, and the share price fall 30%, and you thought you were being clever holding on for an extra 10% or so? | ruethewhirl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions